Reply to 'Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2' by Solimani et al
- PMID: 35679165
- PMCID: PMC9347809
- DOI: 10.1111/jdv.18302
Reply to 'Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2' by Solimani et al
Conflict of interest statement
None to declare for all authors.
Comment on
-
Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2.J Eur Acad Dermatol Venereol. 2021 Oct;35(10):e649-e651. doi: 10.1111/jdv.17480. Epub 2021 Jul 12. J Eur Acad Dermatol Venereol. 2021. PMID: 34169588 Free PMC article. No abstract available.
References
-
- Sahin U, Muik A, Derhovanessian E et al. COVID‐19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses [published correction appears in nature. 2021 Feb;590(7844):E17]. Nature 2020; 586: 594–599. - PubMed
-
- Mulligan MJ, Lyke KE, Kitchin N et al. Phase I/II study of COVID‐19 RNA vaccine BNT162b1 in adults [published correction appears in nature. 2021 Feb;590(7844):E26]. Nature 2020; 586: 589–593. - PubMed
-
- De Simone C, Caldarola G, D'agostino M, Zampetti A, Amerio P, Feliciani C. Exacerbation of pemphigus after influenza vaccination. Clin Exp Dermatol 2008; 33: 718–720. - PubMed
-
- Korang K, Ghohestani R, Krieg T, Uitto J, Hunzelmann N. Exacerbation of pemphigus foliaceus after tetanus vaccination accompanied by synthesis of auto‐antibodies against paraneoplastic pemphigus antigens. Acta Derm Venereol 2002; 82: 482–483. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
